ROMEO (Rosuvastatin in Metabolic syndrOme)

A 6-week, Randomised, Open-label, Parallel Group, Multi-centre Study to Compare the Efficacy of Rosuvastatin 10mg With Atorvastatin 10mg in the Treatment of Metabolic Syndrome Subjects With Raised LDL-C

The primary objective of this study is to compare the effect of rosuvastatin 10mg with atorvastatin 10mg after 6 weeks of treatment in the ratio of ApoB/ApoA1 in subjects with metabolic syndrome.

Inclusion Criteria:

• Presence of 3 or more of the following criteria;

  • Abdominal obesity (men >90cm women >80cm)
  • Triglycerides ≥ 150 mg/dL
  • HDL-C: men < 40 mg/dL, women < 50 mg/dL
  • BP ≥130/≥85 mmHg or anti-hypertensive treatment
  • Fasting blood glucose ≥100 mg dL or anti-diabetic treatment

• Elevated LDL-C ;

  • ≥130 mg/dL to < 220 mg/dL in lipid lowering agent naive subjects
  • ≥100 mg/dL to < 200 mg/dL in subjects who have taken a lipid lowering drug(s) within 4 weeks of visit 1.

• Triglyceride < 500 mg/dL